한글목차

세계의 Drug Discovery용 인공지능 시장 규모는 2024년에 22억 8,100만 달러로 추정되며, 2025년부터 2031년까지 예측 기간 동안 CAGR 30.7%로 성장하여 2031년까지 145억 1,100만 달러로 확대될 것으로 예측됩니다.

의료 분야에서의 인공지능은 기계학습 모델을 이용하여 의료 데이터를 검색하고, 건강 상태 개선 및 환자 경험 향상에 도움이 되는 지식을 도출하는 기술입니다. 최근 컴퓨터 과학과 정보 과학의 발전으로 인공지능(AI)은 현대 의료의 필수적인 요소로 자리 잡고 있습니다. AI 알고리즘 및 기타 AI 기반 애플리케이션은 임상 현장과 지속적인 연구에서 의료 전문가를 지원하기 위해 활용되고 있습니다. 현재 의료 현장에서 AI의 가장 일반적인 역할은 임상 의사결정 지원과 영상 분석입니다. 임상 의사결정 지원 도구는 의료진이 환자와 관련된 정보와 조사에 빠르게 접근할 수 있도록함으로써 치료, 약물, 정신건강 및 기타 환자 요구에 대한 의사결정을 지원합니다. 신약개발은 의약품 개발에서 가장 장기적이고 비용이 많이 드는 과정 중 하나입니다. AI는 크게 두 가지 방법으로 신약 개발 비용 절감에 기여할 수 있습니다 : 우수한 약물 설계의 창출과 유망한 신약 조합의 발견입니다. AI를 활용하면 생명과학 산업이 직면한 많은 빅데이터 문제를 극복할 수 있습니다.

Drug Discovery용 인공지능(AI) 시장의 성장은 새로운 치료제 개발을 가속화하고 비용을 절감해야 하는 시급한 필요성에 의해 주도되고 있습니다. 전통적인 신약 개발 프로세스는 시간이 오래 걸리고, 비용이 많이 들고, 실패율이 높은 경향이 있기 때문입니다. AI는 후보 약물의 신속한 식별, 약물-표적 상호작용 예측 모델링, 임상시험 설계의 최적화를 통해 개발 기간을 크게 단축할 수 있습니다. 유전체학, 단백질체학, 실제 임상 데이터세트를 포함한 바이오메디컬 데이터의 폭발적인 증가는 AI 알고리즘이 새로운 지식을 발견할 수 있는 풍부한 기반을 제공하고 있습니다. 또한, 제약사, 생명공학 기업, 벤처 캐피털의 AI 기반 플랫폼에 대한 투자 증가는 딥러닝, 자연어 처리, 생성 모델의 발전과 함께 AI의 채택을 촉진하고 있습니다. 규제 당국이 AI를 활용한 신약 개발 워크플로우에 대해 개방적인 태도를 보이는 것도 이 혁신적인 분야의 성장을 뒷받침하고 있습니다.

이 보고서는 Drug Discovery용 인공지능 세계 시장에 대해 총 매출액, 주요 기업의 시장 점유율 및 순위를 중심으로 지역/국가별, 유형별, 용도별 분석을 종합적으로 제시하는 것을 목적으로 합니다.

Drug Discovery용 인공지능 시장 규모 추정 및 예측은 매출액 기준으로 제시되며, 2024년을 기준 연도로 2020년부터 2031년까지의 과거 데이터와 예측 데이터를 포함하고 있습니다. 정량적 분석과 정성적 분석을 통해 독자들이 비즈니스/성장 전략 수립, 시장 경쟁 상황 평가, 현재 시장에서의 포지셔닝 분석, 신약개발 분야에서의 인공지능 관련 정보에 입각한 비즈니스 의사결정을 내릴 수 있도록 돕습니다.

시장 세분화

기업별

• IBM
• Exscientia
• Google(Alphabet)
• Microsoft
• Atomwise
• Schrodinger
• Aitia
• Insilico Medicine
• NVIDIA
• XtalPi
• BPGbio
• Owkin
• CytoReason
• Deep Genomics
• Cloud Pharmaceuticals
• BenevolentAI
• Cyclica
• Verge Genomics
• Valo Health
• Envisagenics
• Euretos
• BioAge Labs
• Iktos
• BioSymetrics
• Evaxion Biotech
• Aria Pharmaceuticals, Inc

유형별 부문

• 하드웨어
• 소프트웨어
• 서비스

용도별 부문

• Drug Discovery 초기 단계
• 전임상 단계
• 임상 단계
• 규제 승인

지역별

• 북미
  • 미국
  • 캐나다
• 아시아태평양
  • 중국
  • 일본
  • 한국
  • 동남아시아
  • 인도
  • 호주
  • 기타 아시아태평양
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 네덜란드
  • 북유럽 국가
  • 기타 유럽
• 라틴아메리카
  • 멕시코
  • 브라질
  • 기타 라틴아메리카
• 중동 및 아프리카
  • 튀르키예
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동 및 아프리카

영문목차

The global market for Artificial Intelligence in Drug Discovery was estimated to be worth US$ 2281 million in 2024 and is forecast to a readjusted size of US$ 14511 million by 2031 with a CAGR of 30.7% during the forecast period 2025-2031.

Artificial intelligence in medicine is the use of machine learning models to search medical data and uncover insights to help improve health outcomes and patient experiences. Thanks to recent advances in computer science and informatics, artificial intelligence (AI) is quickly becoming an integral part of modern healthcare. AI algorithms and other applications powered by AI are being used to support medical professionals in clinical settings and in ongoing research. Currently, the most common roles for AI in medical settings are clinical decision support and imaging analysis. Clinical decision support tools help providers make decisions about treatments, medications, mental health and other patient needs by providing them with quick access to information or research that's relevant to their patient. Drug discovery is often one of the longest and most costly parts of drug development. AI could help reduce the costs of developing new medicines in primarily two ways: creating better drug designs and finding promising new drug combinations. With AI, many of the big data challenges facing the life sciences industry could be overcome.

The market for artificial intelligence (AI) in drug discovery is driven by the urgent need to accelerate and reduce the cost of developing new therapeutics, as traditional drug discovery is often slow, expensive, and prone to high failure rates. AI enables rapid identification of drug candidates, predictive modeling of drug-target interactions, and optimization of clinical trial design, significantly shortening development timelines. The explosion of biomedical data, including genomics, proteomics, and real-world clinical datasets, provides a rich foundation for AI algorithms to uncover novel insights. Additionally, rising investment from pharmaceutical companies, biotech firms, and venture capital in AI-driven platforms-combined with advances in deep learning, natural language processing, and generative models-is propelling adoption. Regulatory agencies' increasing openness to AI-assisted drug development workflows also supports the growth of this transformative sector.

This report aims to provide a comprehensive presentation of the global market for Artificial Intelligence in Drug Discovery, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Artificial Intelligence in Drug Discovery by region & country, by Type, and by Application.

The Artificial Intelligence in Drug Discovery market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Artificial Intelligence in Drug Discovery.

Market Segmentation

By Company

• IBM
• Exscientia
• Google(Alphabet)
• Microsoft
• Atomwise
• Schrodinger
• Aitia
• Insilico Medicine
• NVIDIA
• XtalPi
• BPGbio
• Owkin
• CytoReason
• Deep Genomics
• Cloud Pharmaceuticals
• BenevolentAI
• Cyclica
• Verge Genomics
• Valo Health
• Envisagenics
• Euretos
• BioAge Labs
• Iktos
• BioSymetrics
• Evaxion Biotech
• Aria Pharmaceuticals, Inc

Segment by Type

• Hardware
• Software
• Service

Segment by Application

• Early Drug Discovery
• Preclinical Phase
• Clinical Phase
• Regulatory Approval

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Artificial Intelligence in Drug Discovery company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Artificial Intelligence in Drug Discovery in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Artificial Intelligence in Drug Discovery in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Artificial Intelligence in Drug Discovery Product Introduction
• 1.2 Global Artificial Intelligence in Drug Discovery Market Size Forecast (2020-2031)
• 1.3 Artificial Intelligence in Drug Discovery Market Trends & Drivers
  • 1.3.1 Artificial Intelligence in Drug Discovery Industry Trends
  • 1.3.2 Artificial Intelligence in Drug Discovery Market Drivers & Opportunity
  • 1.3.3 Artificial Intelligence in Drug Discovery Market Challenges
  • 1.3.4 Artificial Intelligence in Drug Discovery Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Artificial Intelligence in Drug Discovery Players Revenue Ranking (2024)
• 2.2 Global Artificial Intelligence in Drug Discovery Revenue by Company (2020-2025)
• 2.3 Key Companies Artificial Intelligence in Drug Discovery Manufacturing Base Distribution and Headquarters
• 2.4 Key Companies Artificial Intelligence in Drug Discovery Product Offered
• 2.5 Key Companies Time to Begin Mass Production of Artificial Intelligence in Drug Discovery
• 2.6 Artificial Intelligence in Drug Discovery Market Competitive Analysis
  • 2.6.1 Artificial Intelligence in Drug Discovery Market Concentration Rate (2020-2025)
  • 2.6.2 Global 5 and 10 Largest Companies by Artificial Intelligence in Drug Discovery Revenue in 2024
  • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Artificial Intelligence in Drug Discovery as of 2024)
• 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Hardware
  • 3.1.2 Software
  • 3.1.3 Service
• 3.2 Global Artificial Intelligence in Drug Discovery Sales Value by Type
  • 3.2.1 Global Artificial Intelligence in Drug Discovery Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Artificial Intelligence in Drug Discovery Sales Value, by Type (2020-2031)
  • 3.2.3 Global Artificial Intelligence in Drug Discovery Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Early Drug Discovery
  • 4.1.2 Preclinical Phase
  • 4.1.3 Clinical Phase
  • 4.1.4 Regulatory Approval
• 4.2 Global Artificial Intelligence in Drug Discovery Sales Value by Application
  • 4.2.1 Global Artificial Intelligence in Drug Discovery Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Artificial Intelligence in Drug Discovery Sales Value, by Application (2020-2031)
  • 4.2.3 Global Artificial Intelligence in Drug Discovery Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

• 5.1 Global Artificial Intelligence in Drug Discovery Sales Value by Region
  • 5.1.1 Global Artificial Intelligence in Drug Discovery Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Artificial Intelligence in Drug Discovery Sales Value by Region (2020-2025)
  • 5.1.3 Global Artificial Intelligence in Drug Discovery Sales Value by Region (2026-2031)
  • 5.1.4 Global Artificial Intelligence in Drug Discovery Sales Value by Region (%), (2020-2031)
• 5.2 North America
  • 5.2.1 North America Artificial Intelligence in Drug Discovery Sales Value, 2020-2031
  • 5.2.2 North America Artificial Intelligence in Drug Discovery Sales Value by Country (%), 2024 VS 2031
• 5.3 Europe
  • 5.3.1 Europe Artificial Intelligence in Drug Discovery Sales Value, 2020-2031
  • 5.3.2 Europe Artificial Intelligence in Drug Discovery Sales Value by Country (%), 2024 VS 2031
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific Artificial Intelligence in Drug Discovery Sales Value, 2020-2031
  • 5.4.2 Asia Pacific Artificial Intelligence in Drug Discovery Sales Value by Region (%), 2024 VS 2031
• 5.5 South America
  • 5.5.1 South America Artificial Intelligence in Drug Discovery Sales Value, 2020-2031
  • 5.5.2 South America Artificial Intelligence in Drug Discovery Sales Value by Country (%), 2024 VS 2031
• 5.6 Middle East & Africa
  • 5.6.1 Middle East & Africa Artificial Intelligence in Drug Discovery Sales Value, 2020-2031
  • 5.6.2 Middle East & Africa Artificial Intelligence in Drug Discovery Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Artificial Intelligence in Drug Discovery Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Artificial Intelligence in Drug Discovery Sales Value, 2020-2031
• 6.3 United States
  • 6.3.1 United States Artificial Intelligence in Drug Discovery Sales Value, 2020-2031
  • 6.3.2 United States Artificial Intelligence in Drug Discovery Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Artificial Intelligence in Drug Discovery Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Artificial Intelligence in Drug Discovery Sales Value, 2020-2031
  • 6.4.2 Europe Artificial Intelligence in Drug Discovery Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Artificial Intelligence in Drug Discovery Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Artificial Intelligence in Drug Discovery Sales Value, 2020-2031
  • 6.5.2 China Artificial Intelligence in Drug Discovery Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Artificial Intelligence in Drug Discovery Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Artificial Intelligence in Drug Discovery Sales Value, 2020-2031
  • 6.6.2 Japan Artificial Intelligence in Drug Discovery Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Artificial Intelligence in Drug Discovery Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Artificial Intelligence in Drug Discovery Sales Value, 2020-2031
  • 6.7.2 South Korea Artificial Intelligence in Drug Discovery Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Artificial Intelligence in Drug Discovery Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Artificial Intelligence in Drug Discovery Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Artificial Intelligence in Drug Discovery Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Artificial Intelligence in Drug Discovery Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Artificial Intelligence in Drug Discovery Sales Value, 2020-2031
  • 6.9.2 India Artificial Intelligence in Drug Discovery Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Artificial Intelligence in Drug Discovery Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 IBM
  • 7.1.1 IBM Profile
  • 7.1.2 IBM Main Business
  • 7.1.3 IBM Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.1.4 IBM Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.1.5 IBM Recent Developments
• 7.2 Exscientia
  • 7.2.1 Exscientia Profile
  • 7.2.2 Exscientia Main Business
  • 7.2.3 Exscientia Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.2.4 Exscientia Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.2.5 Exscientia Recent Developments
• 7.3 Google(Alphabet)
  • 7.3.1 Google(Alphabet) Profile
  • 7.3.2 Google(Alphabet) Main Business
  • 7.3.3 Google(Alphabet) Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.3.4 Google(Alphabet) Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.3.5 Google(Alphabet) Recent Developments
• 7.4 Microsoft
  • 7.4.1 Microsoft Profile
  • 7.4.2 Microsoft Main Business
  • 7.4.3 Microsoft Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.4.4 Microsoft Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.4.5 Microsoft Recent Developments
• 7.5 Atomwise
  • 7.5.1 Atomwise Profile
  • 7.5.2 Atomwise Main Business
  • 7.5.3 Atomwise Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.5.4 Atomwise Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.5.5 Atomwise Recent Developments
• 7.6 Schrodinger
  • 7.6.1 Schrodinger Profile
  • 7.6.2 Schrodinger Main Business
  • 7.6.3 Schrodinger Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.6.4 Schrodinger Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.6.5 Schrodinger Recent Developments
• 7.7 Aitia
  • 7.7.1 Aitia Profile
  • 7.7.2 Aitia Main Business
  • 7.7.3 Aitia Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.7.4 Aitia Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.7.5 Aitia Recent Developments
• 7.8 Insilico Medicine
  • 7.8.1 Insilico Medicine Profile
  • 7.8.2 Insilico Medicine Main Business
  • 7.8.3 Insilico Medicine Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.8.4 Insilico Medicine Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.8.5 Insilico Medicine Recent Developments
• 7.9 NVIDIA
  • 7.9.1 NVIDIA Profile
  • 7.9.2 NVIDIA Main Business
  • 7.9.3 NVIDIA Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.9.4 NVIDIA Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.9.5 NVIDIA Recent Developments
• 7.10 XtalPi
  • 7.10.1 XtalPi Profile
  • 7.10.2 XtalPi Main Business
  • 7.10.3 XtalPi Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.10.4 XtalPi Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.10.5 XtalPi Recent Developments
• 7.11 BPGbio
  • 7.11.1 BPGbio Profile
  • 7.11.2 BPGbio Main Business
  • 7.11.3 BPGbio Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.11.4 BPGbio Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.11.5 BPGbio Recent Developments
• 7.12 Owkin
  • 7.12.1 Owkin Profile
  • 7.12.2 Owkin Main Business
  • 7.12.3 Owkin Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.12.4 Owkin Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.12.5 Owkin Recent Developments
• 7.13 CytoReason
  • 7.13.1 CytoReason Profile
  • 7.13.2 CytoReason Main Business
  • 7.13.3 CytoReason Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.13.4 CytoReason Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.13.5 CytoReason Recent Developments
• 7.14 Deep Genomics
  • 7.14.1 Deep Genomics Profile
  • 7.14.2 Deep Genomics Main Business
  • 7.14.3 Deep Genomics Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.14.4 Deep Genomics Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.14.5 Deep Genomics Recent Developments
• 7.15 Cloud Pharmaceuticals
  • 7.15.1 Cloud Pharmaceuticals Profile
  • 7.15.2 Cloud Pharmaceuticals Main Business
  • 7.15.3 Cloud Pharmaceuticals Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.15.4 Cloud Pharmaceuticals Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.15.5 Cloud Pharmaceuticals Recent Developments
• 7.16 BenevolentAI
  • 7.16.1 BenevolentAI Profile
  • 7.16.2 BenevolentAI Main Business
  • 7.16.3 BenevolentAI Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.16.4 BenevolentAI Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.16.5 BenevolentAI Recent Developments
• 7.17 Cyclica
  • 7.17.1 Cyclica Profile
  • 7.17.2 Cyclica Main Business
  • 7.17.3 Cyclica Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.17.4 Cyclica Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.17.5 Cyclica Recent Developments
• 7.18 Verge Genomics
  • 7.18.1 Verge Genomics Profile
  • 7.18.2 Verge Genomics Main Business
  • 7.18.3 Verge Genomics Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.18.4 Verge Genomics Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.18.5 Verge Genomics Recent Developments
• 7.19 Valo Health
  • 7.19.1 Valo Health Profile
  • 7.19.2 Valo Health Main Business
  • 7.19.3 Valo Health Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.19.4 Valo Health Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.19.5 Valo Health Recent Developments
• 7.20 Envisagenics
  • 7.20.1 Envisagenics Profile
  • 7.20.2 Envisagenics Main Business
  • 7.20.3 Envisagenics Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.20.4 Envisagenics Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.20.5 Envisagenics Recent Developments
• 7.21 Euretos
  • 7.21.1 Euretos Profile
  • 7.21.2 Euretos Main Business
  • 7.21.3 Euretos Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.21.4 Euretos Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.21.5 Euretos Recent Developments
• 7.22 BioAge Labs
  • 7.22.1 BioAge Labs Profile
  • 7.22.2 BioAge Labs Main Business
  • 7.22.3 BioAge Labs Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.22.4 BioAge Labs Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.22.5 BioAge Labs Recent Developments
• 7.23 Iktos
  • 7.23.1 Iktos Profile
  • 7.23.2 Iktos Main Business
  • 7.23.3 Iktos Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.23.4 Iktos Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.23.5 Iktos Recent Developments
• 7.24 BioSymetrics
  • 7.24.1 BioSymetrics Profile
  • 7.24.2 BioSymetrics Main Business
  • 7.24.3 BioSymetrics Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.24.4 BioSymetrics Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.24.5 BioSymetrics Recent Developments
• 7.25 Evaxion Biotech
  • 7.25.1 Evaxion Biotech Profile
  • 7.25.2 Evaxion Biotech Main Business
  • 7.25.3 Evaxion Biotech Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.25.4 Evaxion Biotech Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.25.5 Evaxion Biotech Recent Developments
• 7.26 Aria Pharmaceuticals, Inc
  • 7.26.1 Aria Pharmaceuticals, Inc Profile
  • 7.26.2 Aria Pharmaceuticals, Inc Main Business
  • 7.26.3 Aria Pharmaceuticals, Inc Artificial Intelligence in Drug Discovery Products, Services and Solutions
  • 7.26.4 Aria Pharmaceuticals, Inc Artificial Intelligence in Drug Discovery Revenue (US$ Million) & (2020-2025)
  • 7.26.5 Aria Pharmaceuticals, Inc Recent Developments

8 Industry Chain Analysis

• 8.1 Artificial Intelligence in Drug Discovery Industrial Chain
• 8.2 Artificial Intelligence in Drug Discovery Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Artificial Intelligence in Drug Discovery Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Artificial Intelligence in Drug Discovery Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer